Edwards snags CE mark for resilient aortic valve replacement

Inspiris valve

Edwards Lifesciences earned a CE mark for its resilient aortic valve, the first valve that incorporates a novel tissue technology aimed at cutting down calcification that affects other valve replacements.

The Inspiris Resilia valve includes two new features: VFit technology, which is designed to allow for future valve-in-valve procedures, and the resilient bovine tissue tech, dubbed Resilia, which reduces calcification and allows the valve to be stored dry, the company said in a statement. Preclinical studies demonstrated the valve’s ability to reduce calcification and sustain blood flow.

Fighting calcification is important because it causes valve replacements to break down over time. A longer-lasting valve replacement is critical for patients who are now living longer after receiving a valve replacement as well as for younger patients receiving valve replacements. The Resilia technology not only prevents calcification once implanted in the body, but also during storage. Valves that must be stored in liquid solutions may calcify in storage, an issue that does not affect the Inspiris valve because it is stored dry.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The CE mark is based on data from a pivotal trial also conducted for U.S. premarket approval. One-year data from 673 patients showed no instances of structural valve deterioration, valve thrombosis or clotting, or nonstructural valve dysfunction, according to the statement. Three-year results from the trial will be unveiled next month.

Edwards is planning a limited launch of the device in Europe in the fourth quarter this year, with full commercialization to follow in Q1 2017. The company did not indicate plans for the U.S. market, though an FDA nod for the device is anticipated for next year. And while the CE mark is for use in the aorta, the valve is in development for mitral and pulmonary valve replacement as well.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.